News & Events

Meet selectION, Inc. at the BIO International Convention in Boston, on June 5^th to 8^th, 2023

May 9, 2023

SAN DIEGO, May 9, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the Phase 1b clinical trial in autoimmune…

Meet selectION, Inc. at the BIO-EUROPE SPRING Conference in Basel, Switzerland, on March 20^th to March 22^nd, 2023

February 9, 2023

Events

SAN DIEGO, February 9, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.

Meet selectION, Inc. at the Global Life Science Partnering & Investor Conference in La Jolla, CA, on February 28^th to March 2^nd, 2023

February 1, 2023

Events

SAN DIEGO, February 1, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis.

Meet selectION, Inc. at the 41^stAnnual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 9^th to 12^th, 2023

December 1, 2022

Events

SAN DIEGO, December 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Steve Zaniboni (CFO) for an update on selectION’s clinical work in atopic dermatitis.

Meet selectION, Inc. at the BioEurope 2022 Partnering Conference in Leipzig on October 24^th to 26^th, 2022

October 1, 2022

Events

SAN DIEGO, October 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Andreas Klostermann, Ph.D. (CSO) for an update on selectION’s best-in-class ion channel blockers and the status of the…

selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients

September 12, 2022

News

Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12,…

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

May 9, 2022

News

Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality – San Diego, CA, USA, and Munich, Germany – May 09, 2022…

Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22^nd to 24^th, 2022

January 11, 2022

Events

SAN DIEGO, January 11, 2022 – Meet Antonius Schuh, Ph.D. (CEO), Andreas Klostermann, Ph.D. (CSO) and Steve Zaniboni (CFO) for an update on selectION’s best-in-class ion channel blockers and the…

Meet selectION, Inc. at the Biocom’s Virtual Global Life Science Partnering Conference on February 23^rd to 25^th, 2021

January 10, 2021

Events

SAN DIEGO, January 10, 2021 – Meet Antonius Schuh, Ph.D. (CEO) and Andreas Klostermann, Ph.D. (CSO) for an update on selectION’s best-in-class ion channel blockers and the status of the…

selectION Secures $5M Promissory Note

September 16, 2020

News

si-544, a Kv1.3 blocker with class leading selectivity and excellent preclinical safety profile, scheduled to advance towards clinical development in early 2021 SAN DIEGO, September 16, 2020 – selectION, Inc.…

News & Events

Meet selectION, Inc. at the BIO International Convention in Boston, on June 5^th to 8^th, 2023

Meet selectION, Inc. at the BIO-EUROPE SPRING Conference in Basel, Switzerland, on March 20^th to March 22^nd, 2023

Meet selectION, Inc. at the Global Life Science Partnering & Investor Conference in La Jolla, CA, on February 28^th to March 2^nd, 2023

Meet selectION, Inc. at the 41^stAnnual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 9^th to 12^th, 2023

Meet selectION, Inc. at the BioEurope 2022 Partnering Conference in Leipzig on October 24^th to 26^th, 2022

selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22^nd to 24^th, 2022

Meet selectION, Inc. at the Biocom’s Virtual Global Life Science Partnering Conference on February 23^rd to 25^th, 2021

selectION Secures $5M Promissory Note

Site Search

News Categories

Recent News

About

Recent News

Contact